M13 therapeutics (now GENSAIC) is harnessing the phageome to engineer a diverse set of immune-privileged gene delivery nanoparticles, called phage-derived particles (PDPs), for targeted human cell transduction. The bacteriophage-based platform is a highly modular system with engineerable protein capsids and designer minimal phage DNA (mpDNA) cargos. PDPs offer durable therapeutic efficacy via repeat administration, enable tissue-specific targeting, support massively scalable manufacturing, and can package any full-length human gene as a therapeutic (>20 kb). M13 Therapeutics (now GENSAIC) is driven by the mission to treat human disease and create impactful science in the field of genomic medicines.